Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366
Karine Dubé(University of North Carolina at Chapel Hill), Eileen P. Scully(Johns Hopkins University), Catherine Godfrey(United States Department of State), Brandon Brown(University of California, Riverside), Jane M. Simoni(University of Washington), John A. Sauceda(San Francisco AIDS Foundation), Rajesh T. Gandhi(Harvard University), Kate Starr(Columbus Center), Jeremy Sugarman(Johns Hopkins Berman Institute of Bioethics), Lara Hosey(Social and Scientific Systems (United States)), Daniel R. Kuritzkes(Brigham and Women's Hospital), David A. Wohl(University of North Carolina at Chapel Hill), Erin Hoffman(University of North Carolina at Chapel Hill), Karen Diepstra(University of North Carolina at Chapel Hill), Danielle Campbell(Delaney AIDS Research Enterprise), David Evans(Advisory Board Company (United States)), Elizabeth Barr(Office of the Director)
Cited by 37
Related Papers
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847